Clinical Trial Update: To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics and safety study evaluating selumetinib in renal-impaired and healthy subjects has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Selumetinib (selumetinib)

Snippet

Sponsor: AstraZeneca | Conditions: Solid Tumours | Phase 1 | Status: COMPLETED